Patents by Inventor John L. Diener

John L. Diener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aptamers comprising CPG motifs
    Patent number: 10100316
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: October 16, 2018
    Assignee: Archemix LLC
    Inventors: David Epstein, Dilara Grate, Martin Stanton, John L. Diener, Charles Wilson, Thomas Greene McCauley, Errol Desouza
  • Methods for identifying aptamer regulators
    Patent number: 9303262
    Abstract: Methods are provided for identifying aptamer regulators. Aptamer regulators are aptamers that bind to a target wherein binding of the aptamer regulator to the target increases the binding affinity of the target for a target partner relative to the affinity of the target for the target partner when the target is not bound by the aptamer regulator such that binding of the aptamer regulator to the target is a prerequisite for target-target partner complex formation.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: April 5, 2016
    Assignee: ARCHEMIX LLC
    Inventors: Charles Wilson, David Epstein, John L. Diener
  • Stabilized Aptamers to Platelet Derived Growth Factor and Their Use as Oncology Therapeutics
    Publication number: 20160053266
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: September 9, 2015
    Publication date: February 25, 2016
    Applicant: ARCHEMIX LLC
    Inventors: Dilara McCauley, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 9080175
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 14, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • STABILIZED APTAMERS TO PLATELET DERIVED GROWTH FACTOR AND THEIR USE AS ONCOLOGY THERAPEUTICS
    Publication number: 20150140120
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptarmers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: October 3, 2014
    Publication date: May 21, 2015
    Applicant: ARCHEMIX LLC
    Inventors: Dilara McCauley, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
    Patent number: 8853376
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: October 7, 2014
    Assignee: Archemix LLC
    Inventors: Dilara McCauley, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • ORGANIC COMPOSITIONS TO TREAT Beta-ENaC-RELATED DISEASES
    Publication number: 20140107179
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 17, 2014
    Applicant: Novartis AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew Griffin SPRAGUE
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20130012571
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 8344130
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic compositions to treat beta-ENaC-related diseases
    Patent number: 8344131
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 8344129
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic compositions to treat beta-ENaC-related diseases
    Patent number: 8344127
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Sprague
  • Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
    Patent number: 8252913
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: August 28, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Robert G. Schaub, Kathleen McGinness, Jennifer Nelson, Ryan Genga, Emily Waters, Jeffrey C. Kurz, John L. Diener
  • Stabilized Aptamers To Platelet Derived Growth Factor And Their Use As Oncology Therapeutics
    Publication number: 20120171304
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: September 16, 2011
    Publication date: July 5, 2012
    Inventors: Dilara Grate, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • APTAMERS THAT BIND THROMBIN WITH HIGH AFFINITY
    Publication number: 20120149764
    Abstract: The invention provides aptamers capable of binding to thrombin useful as therapeutics for and diagnostics of coagulation related disorders and/or other diseases or disorders in which thrombin has been implicated. The invention further provides materials and methods for the administration of aptamers capable of binding to thrombin.
    Type: Application
    Filed: August 15, 2011
    Publication date: June 14, 2012
    Inventors: John L. Diener, Jess Wagner-Whyte, David Fontana
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120122960
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 17, 2012
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120115933
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 10, 2012
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120115934
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 10, 2012
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Materials and methods for the generation of fully 2?-modified nucleic acid transcripts
    Patent number: 8105813
    Abstract: Materials and methods are provided for producing aptamer therapeutics having fully modified nucleotide triphosphates incorporated into their sequence.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: January 31, 2012
    Assignee: Archemix Corp.
    Inventors: John L. Diener, Anthony Dominic Keefe, Kristin Thompson, Chunhua Wang, Shuhao Zhu
  • Materials and methods for the generation of transcripts comprising modified nucleotides
    Patent number: 8101385
    Abstract: Materials and methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: January 24, 2012
    Assignee: Archemix Corp.
    Inventors: Sharon Cload, John L. Diener, Anthony Dominic Keefe, Kristin Thompson